Arca
Skip to content

Relapsed and/or refractory b-cell lymphoma

Drug research and approvals for relapsed and/or refractory b-cell lymphoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 189 studies of relapsed and/or refractory b-cell lymphoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 15 drug trials for it since 2013.

  • Recruiting worldwide: 189
  • Trials authorized in Canada: 15
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 189 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 15; search them all in Canada trials
Mar 11, 2026A phase 1/2 open-label, multicenter study evaluating the safety and efficacy of kite-363 or kite-753, autologous anti-cd19/cd20 car t-cell therapies, in…KITE-753KITEPHARMA INCOngoing
Feb 20, 2026A phase 3 randomized controlled trial of rondecabtagene autoleucel, an autologous, dual-targeting cd19/cd20 car t-cell product candidate, versus investigator’s…RONDECABTAGENE AUTOLEUCELLYELL IMMUNOPHARMA, INCOngoing
Dec 13, 2024A phase II, open-label, multicenter study to evaluate the optimization of the cytokine release syndrome profile for glofitamab in combination with gemcitabine…COLUMVI / GAZYVARocheOngoing
Jul 2, 2024An open-label, phase I/ii study to evaluate the safety, pharmacokinetics and preliminary anti-tumor activity of englumafusp alfa (ro7227166, a cd19 targeted…ENGLUMAFUSP ALFA (RO7227166) / GLOFITAMAB / GAZYVA / ACTEMRA (FOREIGN-MARKET…RocheOngoing
Jun 13, 2024Relapsed or refractory diffuse large b-cell lymphoma: phase 3 study to evaluate the safety and efficacy of epcoritamab plus lenalidomide compared to rituximab…EPCORITAMAB / LENALIDOMIDE / RITUXIMAB / GEMCITABINE / OXALIPLATIN / TOCILIZUMABAbbVieOngoing
Nov 30, 2023Expanded access protocol (eap) for subjects receiving lisocabtagene maraleucel that is nonconforming to commercial releaseBREYANZI (LISOCABTAGENE MARALEUCEL (JCAR017))Bristol-Myers SquibbOngoing
Dec 22, 2022A single-arm, open-label, phase 1/2 study evaluating the safety, efficacy, and cellular kinetics/pharmacodynamics of allo-501a, an anti-cd-19 allogeneic car t…ALLO-501A / ALLO-647 / FLUDARABINE PHOSPHATE / CYCLOPHOSPHAMIDEALLOGENE THERAPEUTICS INCOngoing
Feb 25, 2022A phase 2 non-randomized, open-label, multi-cohort, multicenter study assessing the clinical benefit of sar444245 (thor-707) with or without other anticancer…SAR444245 / TOCILIZUMAB / PEMBROLIZUMABSANOFI-AVENTIS CANADA INCClosed
Jun 23, 2021An open-label, phase 2 trial of nanatinostat in combination with valganciclovir in patients with epstein-barr virus-positive (ebv+) relapsed/refractory…NANATINOSTAT/ VALGANCICLOVIR/ GANCICLOVIRVIRACTA THERAPEUTICS INC.Closed
Mar 4, 2020A phase 1/2, open-label, dose-escalation trial of gen3013 in patients with relapsed, progressive or refractory b-cell lymphomaGEN3013 (DUOBODY-CD3XCD20)GenmabOngoing

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.